News on research and diagnostic development for pathogenic diseases.
New funding will support assay development and lab space to offer test services, and ultimately a test kit using the firm's resistance database.
Researchers showed that the test had equivalent results to a lab-based assay and has the potential for a faster turnaround time.
Its most advanced gene expression signatures are for infectious disease diagnostics and are aimed at enabling the appropriate prescription of antiviral and antibiotic medications.
MSK researchers showed that high TMB may be associated with improved survival across tumor types, but the cut-offs for high and low status will vary based on histology.
Meridian CEO Jack Kenny said the firm needs to develop a new MDx platform, while Genapsys resurfaced with an update on its portable sequencing platform.
